Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation Research
Search: search_blue_button Advanced Search
Circulation Research. 2006;98:720-722
doi: 10.1161/01.RES.0000217595.42099.8b
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bornfeldt, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bornfeldt, K. E.
Related Collections
Right arrowRelated Article
(Circulation Research. 2006;98:720.)
© 2006 American Heart Association, Inc.


Editorial

Nuclear Signaling in Smooth Muscle Cells

Cyclic Nucleotide Phosphodiesterase 1A Moves In

Karin E. Bornfeldt

From the Department of Pathology, University of Washington School of Medicine, Seattle.

Correspondence to Karin E. Bornfeldt, Department of Pathology, Box 357470, University of Washington School of Medicine, Seattle, WA 98195-7470. E-mail bornf@u.washington.edu



See related article, pages 777–784


Key Words: cyclic GMP • cyclic nucleotide phosphodiestaerases • cytoskeleton • editorials • proliferation • smooth muscle cell


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 


*    Introduction
 
The second messenger cyclic GMP (cGMP) mediates signaling in the nervous system, genitourinary system, and the gastrointestinal tract. In the cardiovascular system, cGMP regulates vasorelaxation, vascular remodeling, platelet activation, and cardiac contractility. The ability of cGMP to regulate such a large number of temporally and spatially disparate processes is attributable to the many different isozymes that exist for synthesis and degradation of cGMP. These enzymes exhibit different subcellular localization and mechanisms of activation. Thus, cGMP is synthesized from GTP by both soluble and particulate forms of guanylyl cyclase. Soluble guanylyl cyclases are heterodimeric cytosolic enzymes that consist of {alpha} and ß subunits. There are several isoforms of the {alpha} and ß subunit, {alpha}1ß1 being the most abundant combination in mammalian tissues.1–3 Soluble guanylyl cyclase is activated by nitric oxide (NO) and NO-releasing drugs. Particulate forms of guanylyl cyclase, on the other hand, are transmembrane proteins that are activated by the natriuretic peptides ANP, BNP, and CNP.4 Similarly, cGMP is degraded by a large number of cyclic nucleotide phosphodiesterases (PDEs). To date, 21 different PDE genes divided among 11 gene families have been identified in mammals. Most PDE families contain more than one gene, and most genes code for more than one mRNA. Although some PDE gene families hydrolyze cAMP exclusively (PDE4, PDE7, PDE8), many of these enzymes hydrolyze cGMP, or both cAMP and cGMP.5 PDE5 is the major cGMP-specific PDE gene family in some cell types. Other cGMP-hydrolyzing PDE gene families include PDE1, PDE2, PDE6, PDE9, PDE10, PDE11, and possibly PDE3.6 Any . . . [Full Text of this Article]


Related Article:

Role of Nuclear Ca2+/Calmodulin-Stimulated Phosphodiesterase 1A in Vascular Smooth Muscle Cell Growth and Survival
David J. Nagel, Toru Aizawa, Kye-Im Jeon, Weimin Liu, Amy Mohan, Heng Wei, Joseph M. Miano, Vincent A. Florio, Pingjin Gao, Vyacheslav A. Korshunov, Bradford C. Berk, and Chen Yan
Circ. Res. 2006 98: 777-784. [Abstract] [Full Text] [PDF]